We'll discuss the challenges, opportunities and value that a patient-centric model presents for drug development.
It’s always interesting to check out what our customers are up to with our platform, and right now Cancer Research UK has a great exploratory trial under way with the experimental drug AMG 319.
What are some of the metrics that can be useful for risk-based monitoring?
Katie Mostek, director, Cardiovascular Research, MidMichigan Health, talks about how it’s becoming increasingly difficult for clinical research sites to be reimbursed for work already completed.
Think we’re biased in our belief that technology will improve the payments process for sites?